More recently, we demonstrated that PDE5 was differentially expressed among breast cancer molecular subtypes, with higher levels in HER2-enriched and triple-negative subtypes compared to the more favourable estrogen receptor (ER)-positive Luminal B- and the Luminal A subtypes [7]. Here, PDE5A is linked to breast cancer.